Enclomiphene
The active isomer of clomiphene with potential for raising testosterone while preserving fertility, but not FDA-approved.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Enclomiphene
The active isomer of clomiphene with potential for raising testosterone while preserving fertility, but not FDA-approved.
Evidence category: Preclinical. This describes the source category, not approval or certainty.
Regulatory statement in source: Not FDA-approved.
Enclomiphene is the active isomer of clomiphene citrate (the other isomer, zuclomiphene, may antagonize desired effects). It functions as a non-steroidal SERM, antagonizing estrogen receptors in the hypothalamus to increase gonadotropin-releasing hormone and stimulate endogenous testosterone production. Unlike testosterone replacement therapy, it preserves spermatogenesis. Not FDA-approved; used through compounding under specialist supervision.
Benefits reported in the imported source
- May raise testosterone in hypogonadal men while preserving fertility (unlike TRT)
- Maintains FSH/LH levels and intratesticular testosterone
Risks and limits
- Available only through compounding under specialist judgment
- Limited long-term human data
Source bottom line: Preclinical evidence and specialized use only; not FDA-approved despite in vitro efficacy and small clinical studies.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
Men with secondary hypogonadism
- Reported regimen
- Oral SERM; increase in total testosterone compared to placebo
- Duration
- Studies varied in duration
- Reported outcome
- Significant increase in total testosterone (273.76 ng/dL above placebo); non-significant difference vs. topical testosterone gel; preserved sperm concentration
- Source
- Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate - PubMed Central (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
Claim provenance
evidence.json#/catalog:hormone:enclomiphene/protocols/0
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — Enclomiphene Dosage & Protocol - Biomogging
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A community protocol guide identifies 12.5 mg daily as the standard 'community sweet spot', with post-cycle therapy at 12.5 mg for 4 weeks and moderate-to-heavy cycle recovery extending to 12.5-25 mg daily for 6-8 weeks.
Pharmacokinetic context
No half-life recorded in this source snapshot. No value has been inferred.
Source references
- Clomiphene or Enclomiphene for Male Hypogonadism - PubMed Central
- Enclomiphene and Fertility - Good Health by Hims (availability check 2026-10-15: source not retrieved; HTTP 403)
- Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate - PubMed Central (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
Snapshot provenance
Source ID: catalog:hormone:enclomiphene. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.